enbrel overhang rear-view mirror think
invest summari reiter neutral rate pt
friday us district nj court rule favor valid
two patent relat enbrel lift biggest overhang share
view although enbrel revenu estim decreas yoy base
case assum meaning eros biosimilar enbrel
lost would meaning downsid number cours
novarti nc like appeal think rule lift major overhang
share would expect stock least post rule
chang enbrel estim result rule still expect
enbrel experi competit newer therapi especi
dermatolog competitor biosimilar beyond expect
humira lose exclus us assum could potenti affect
enbrel well near term risk although may remain
cleanest large-cap biotech stock perhap view
slow base busi pipelin shot goal larg amount
cash could transform base busi experienc
eros biosimiliar gener legaci product like neulasta epogen
sensipar howev new product help off-set eros like aimovig kyproli
repatha model year year revenu growth
next month think investor remain focus pipelin
potenti sinc could realli drive signific upsid
kra remain four-lett word potenti drive
share seen patient nsclc limit
durabl updat world lung earli septemb would
expect potenti see durabl nsclc respons colorect
manag note call think updat key catalyst
stock care large-scal would
guess visibl enbrel might key factor think deal
well might expect deal activ enbrel like
rear-view mirror
biosimilar busi think investor may under-appreci
revenu may help off-set base busi eros well model
revenu biosimilar develop
disclosur section may found page
use probability-adjust dcf analysi valu share assum discount
rate model revenu assum termin valu roughli
valuat base termin valu reflect compani intern
 engin pipelin program yet model
risk price target neutral rate includ greater-than-expect eros
base busi challeng earn project payer price challeng new
current product late-stag pipelin setback unexpect earli success pipelin asset
sever largest product biosimilar threat emerg come quarter
compani oper payer sensit market particularli cardiovascular diseas
repatha compani also robust early-stag pipelin given credit
either signific upsid downsid to/from program remain risk rate
price target
diversifi biopharmaceut compani special six therapeut area cardiovascular diseas oncolog bone health
neurosci nephrolog inflamm compani also grow biosimilar franchis
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker inc
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
report inform purpos base publicli avail data believ reliabl represent made data
accur complet opinion project contain herein reflect opinion date report subject chang pursuant
cantor fitzgerald polici author report share compani he/sh cover
cantor fitzgerald cantor fitzgerald logo trademark regist trademark cantor fitzgerald secur affili
countri trademark appear herein properti respect owner neither cantor fitzgerald secur affili
associ affili third parti
materi present sole institut commun meant view complet fundament analysi secur
materi may offer recommend strategi shorter term natur materi contain analysi may narrowli focus
may base either pure quantit model uniqu factor market supply/demand factor surround potenti market move
event make invest decis inform view one factor invest decis process past perform
taken indic guarante futur result
disclosur uk investor
materi approv distribut unit kingdom cantor fitzgerald europ cfe cfe authoris regul
conduct author fca believ inform materi upon inform base accur except
oblig rule fca guarante accuraci materi intend use elig counterparti profession
client fall within articl servic market act promot order gener invest
public none invest invest servic mention describ herein avail person particular
avail retail client defin rule fca
disclosur canadian institut investor
research report prepar analyst cantor fitzgerald co cantor fitzgerald canada corpor result report
prepar subject canadian disclosur requir cantor fitzgerald canada may distribut research report prepar affili
financi instrument discuss report may suitabl investor investor must make invest decis base
specif invest object past perform taken indic guarante futur perform price valu
incom financi instrument featur report rise well fall affect chang econom financi polit
factor financi instrument denomin currenc investor currenc chang exchang rate may advers affect price
valu incom deriv financi instrument investor effect assum currenc risk addit investor secur
adr whose valu affect currenc home market underli secur effect assum currenc risk
rate price target histori amgen inc
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
distribut ratings/invest bank servic ib
addit inform avail request copyright cantor fitzgerald
head healthcar research
